Financials data is unavailable for this security.
View more
Year on year Astellas Pharma Inc had net income fall -82.73% from 98.71bn to 17.05bn despite a 5.60% increase in revenues from 1.52tn to 1.60tn. An increase in the selling, general and administrative costs as a percentage of sales from 41.50% to 46.15% was a component in the falling net income despite rising revenues.
| Gross margin | 81.76% |
|---|---|
| Net profit margin | 1.06% |
| Operating margin | 1.59% |
| Return on assets | 0.57% |
|---|---|
| Return on equity | 1.10% |
| Return on investment | 0.85% |
More ▼
Cash flow in JPYView more
In 2024, cash reserves at Astellas Pharma Inc fell by 41.15bn. Cash Flow from Financing totalled 614.06bn or 38.29% of revenues. In addition the company generated 172.48bn in cash from operations while cash used for investing totalled 845.80bn.
| Cash flow per share | 97.33 |
|---|---|
| Price/Cash flow per share | 15.67 |
| Book value per share | 890.07 |
|---|---|
| Tangible book value per share | -154.22 |
More ▼
Balance sheet in JPYView more
| Current ratio | 0.9292 |
|---|---|
| Quick ratio | 0.7358 |
| Total debt/total equity | 0.5765 |
|---|---|
| Total debt/total capital | 0.3657 |
More ▼
Growth rates in JPY
Year on year, growth in dividends per share increased 16.67% while earnings per share excluding extraordinary items fell by -82.43%. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is in-line with the industry average relative to its peers, while earnings per share growth is below the industry average.
| Div yield(5 year avg) | 2.59% |
|---|---|
| Div growth rate (5 year) | 13.00% |
| Payout ratio (TTM) | 371.45% |
| EPS growth(5 years) | -39.26 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -82.58 |
More ▼
